|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Veno occlusive disease: Update on clinical management显示文摘Hepatic veno-occlusive disease is a clinical syndrome characterized by hepatomegaly, ascites, weight gain and jaundice, due to sinusoidal congestion which can be caused by alkaloid ingestion, but the most frequent cause is haematopoietic stem cell transplantation (STC) and is also seen after solid organ transplantation. The incidence of veno occlusive disease (VOD) after STC ranges from 0 to 70%, but is decreasing. Survival is good when VOD is a mild form, but when it is severe and associated with an increase of hepatic venous pressure gradient > 20 mmHg, and mortality is about 90%. Prevention remains the best therapeutic strategy, by using non-myeloablative conditioning regimens before STC. Prophylactic administration of ursodeoxycholic acid, being an antioxidant and antiapoptotic agent, can have some benefit in reducing overall mortality. Defibrotide, which has pro-fibrinolytic and antithrombotic properties, is the most effective therapy; decompression of the sinusoids by a transjugular intrahepatic portosystemic shunt (TIPS) can be tried, especially to treat VOD after liver transplantation and when multiorgan failure (MOF) is not present. Liver transplantation can be the last option, but can not be considered a standard rescue therapy, because usually the concomitant presence of multiorgan failure contraindicates this procedure. | M Senzolo G Germani E Cholongitas P Burra AK Burroughs | 2007 | World Journal of Gastroenterology2007，13，29： | 19 |
| 2 | New insights into the coagulopathy of liver disease and liver transplantation显示文摘The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis. Only von Willebrand factor is not synthetised by the liver, thus liver failure is associated with impairment of coagulation. However, recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease. Therefore, these patients might not be really anticoagulated in stable condition and bleeding may be caused only when additional factors, such as infections, supervene. Portal hypertension plays an important role in coagulopathy in liver disease, reducing the number of circulating platelets, but platelet function and secretion of thrombopoietin have been also shown to be impaired in patients with liver disease. Vitamin K deficiency may coexist, so that abnormal clotting factors are produced due to lack of gamma carboxylation. Moreover during liver failure, there is a reduced capacity to clear activated haemostatic proteins and protein inhibitor complexes from the circulation. Usually therapy for coagulation disorders in liver disease is needed only during bleeding or before invasive procedures. When end stage liver disease occurs, liver transplantation is the only treatment available, which can restore normal haemostasis, and correct genetic clotting defects, such as haemophilia or factor V Leiden mutation. During liver transplantation haemorrage may occur due to the pre-existing hypocoagulable state, the collateral circulation caused by portal hypertension and increased fibrinolysis which occurs during this surgery. | M Senzolo P Burra E Cholongitas AK Burroughs | 2006 | World Journal of Gastroenterology2006，12，48： | 12 |
| 3 | Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference显示文摘 | Jordi Bruix Morris Sherman Josep M Llovet Michel Beaugrand Riccardo Lencioni Andrew K Burroughs Erik Christensen Luigi Pagliaro Massimo Colombo Juan Rodés | 2001 | Journal of Hepatology2001，，3： | 11 |
| 4 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet2003，，9399： | 6 |
| 5 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet2003，，9399： | 4 |
| 6 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet2003，，9399： | 4 |
| 7 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet . 2003 (9399)2003，，： | 3 |
| 8 | Review article: Portal vein thrombosis-new insights into aetiology and management 显示文摘 | Webster G J Burroughs A K Riordan S M | 2005 | Aliment Pharmacol Ther2005，21，1： | 1 |
| 9 | What Users Want: Assessing GovernmentInformation Preferences to Drive Information Services显示文摘 | Jennie M Burroughs | 2009 | Gov-ernment Information Quarterly2009，26，1： | 1 |
| 10 | Transjugular intrahepatic porto- systemic shunt versus endoscopic therapy; randomized trials for secondary prophylaxis of vaficeal bleeding, an updated rneta - analysis显示文摘 | BURROUGHS AK VANGELI M | 2002 | Scand J Gastroenterol2002，37，3： | 1 |
| 11 | Grading of cellular rejection after orthotopic liver transplantation 显示文摘 | Hudson M Burroughs AK | 1995 | Hepatology1995，21，1： | 1 |
| 12 | Immunization of pediatric solid organ transplant candidates and recipients显示文摘 | Burroughs M Moscona A | 2000 | Clinical Infectious Diseases2000，，06： | 1 |
| 13 | Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis显示文摘 | L Grellier D Mutimer M Ahmed D Brown AK Burroughs K Rolles P McMaster P Beranek F Kennedy H Kibbler P McPhillips E Elias G Dusheiko | 1996 | 1996 (9036)1996，，9036： | 1 |
| 14 | Using CAS to Solve Classical Mathematics Problems显示文摘 | Burke M J Burroughs E A | 2009 | Mathematics Teacher2009，102，9： | 1 |
| 15 | Immunologic reeonstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient 显示文摘 | LIU P SANTISTEBAN I BURROUGHS L M | 2009 | Clin Immunol2009，130，2： | 1 |
| 16 | Evolutionary genomics of the HAD superfamily:understanding the structural adaptations and catalytic diversity in a superfam-ily of phosphoesterases and allied enzymes显示文摘 | Burroughs A M Allen K N Dunaway-Mariano D | 2006 | J Mol Biol 20062006，，： | 1 |
| 17 | Desmopressin and bleeding time in patients with cirrhosis显示文摘 | Burroughs AK Matthews K Quadira M | | 0，，： | 1 |
| 18 | Review article:portal vein thrombosis-new insights into aetiology and management显示文摘 | Webster G J Burroughs A K Riordan S M | 2005 | Aliment Pharmacol Theory2005，21，1： | 1 |
| 19 | The men-tor's perspective: A qualitative inquiry and future re- search agenda显示文摘 | Allen T D Poteet M L Burroughs S M | 1997 | Journal of Vocational Behavior1997，51，1： | 1 |
| 20 | The atomic structure of the bluetongue virus core显示文摘 | Burroughs J N Gouet P | 1998 | Nature1998，395，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员